It includes CD40 agonists, CSF-1R inhibitors, CD11b agonists, CCR2 inhibitors, BTK inhibitors, and emerging chemokine receptor inhibitors, such as CXCR2 and CXCR4 antagonists, highlighting the diverse immune modulating approaches to reprogram the immunosuppressive tumor microenvironment. Here, BTK is linked to neoplasm.